Omidenepag isopropyl, a prodrug, is hydrolyzed in the eye to the active form (Omidenepag) which functions as a selective, nonprostaglandin, prostanoid EP2 agonist, has been developed by Ube Industries and Santen Pharmaceutical as an ophthalmic solution (EYBELIS®) for the treatment of glaucoma and ocular hypertension. Omidenepag isopropyl increases the outfow of aqueous humor via both the uveoscleral outfow and the trabecular outfow pathways, resulting in potent and stable reduction in intraocular pressure (IOP). In September 2018, omidenepag isopropyl ophthalmic solution 0.002% was approved in Japan for the treatment of glaucoma and ocular hypertension. On September 22, 2022, the FDA approved Santen’s Omlonti (omidenepag isopropyl), for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Isopropyl palmitate is the ester of isopropyl alcohol and palmitic acid. It is an emollient, moisturizer, thickening agent, and anti-static agent. Isopropyl Palmitate is a traditional, fast spreading emollient for modern cosmetic applications. Isopropyl palmitate is approved by ECOCERT for Natural and Organic Cosmetics. It is on FDA CFR - Code of Federal Regulations Title 21 list.

Alprostadil isopropyl ester induces a considerable and rapidly appearing increased negativity of interstitial fluid pressure in skin that will enhance edema formation. It is able to inhibit contraction of fibroblast-populated collagen gels, which depends on b1-integrin function. Taken together, Alprostadil isopropyl ester can modulate e interstitial fluid volume and interstitial fluid pressure through effects on the connective tissue cells and extracellular matrix components. Alprostadil isopropyl ester was a test compound in preclinical studies of a selective EP2 and EP4 prostanoid receptor agonists for the treatment of female sexual dysfunction.